TCRX Q1 2023 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+125.2% YoY

Gross Profit

$7M100.0% margin

Operating Income

-$23M-334.3% margin

Net Income

-$23M-331.7% margin

EPS (Diluted)

$-0.93

QoQ Revenue Growth

+119.8%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$174M

Total Liabilities

$96M

Stockholders' Equity

$78M

Cash & Equivalents

$96M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$3M	+125.2%
Gross Profit	$7M	-$12M	+158.3%
Operating Income	-$23M	-$16M	-40.7%
Net Income	-$23M	-$16M	-39.7%